BAYER BACKS OFF RUNNING CASEBIA JV, AS CRISPR TX TAKES OVER MANAGEMENT

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics, the German...

VERSEAU BAGS $50M FOR CANCER R&D, NAMES GOLUMBESKI AS CHAIRMAN

Verseau Therapeutics has raised $50 million to develop macrophage-targeted immunotherapies. The startup, which appointed George Golumbeski...

 
 
 

AERPIO MAY HANG THE 'FOR SALE' SIGN UP, AXES CEO AFTER EYE DRUG FLOP

In a classic plot line for biotechs, Aerpio is seeking a “strategic review” for its business and assets after being hit by a trial...

SEATTLE GENETICS' BREAST CANCER DRUG HITS MARK IN PIVOTAL TRIAL

A pivotal trial of Seattle Genetics' tucatinib in patients with HER2-positive breast cancer has met its primary endpoint. The data...

 
 
 

MIRATI SETS DATE FOR CLOSELY WATCHED CLINICAL KRAS READOUT

Mirati Therapeutics is set to reveal the first clinical data on its closely watched KRAS G12C inhibitor MRTX849 Oct. 28. The readout...

CHUTES & LADDERS-GILEAD SCIENCES NAMES DICKINSON TO CFO ROLE

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

 
 
 

UCB'S BISPECIFIC BEATS J&J'S STELARA IN PSORIASIS PHASE 3 

UCB's bimekizumab has beaten Johnson & Johnson's Stelara in a phase 3 psoriasis trial. The bispecific inhibitor of IL-17A and IL-17F...

EUROPEAN VC SOFINNOVA RAISES €333M FOR EARLY-STAGE BIOTECH, MEDTECH FIRMS

Europe-based venture capital company Sofinnova Partners has raised a meaty €333 million in an oversubscribed round to boost life science...

 
 
 

ASTRAZENECA GETS Q2 2020 PDUFA DATE FOR BREAST CANCER ADC

The FDA is set to decide whether to approve AstraZeneca's HER2-targeting antibody-drug conjugate in the second quarter of next year....

SYROS CANS SOLID TUMOR DRUG AFTER SEEING EARLY CLINICAL DATA

Syros Pharmaceuticals has stopped development of its intravenous CDK7 inhibitor SY-1365 after early clinical data came up short. The...

 
 
 

ARSENALBIO JOINS NEXT-GEN CELL THERAPY FIELD WITH $85M A ROUND

ArsenalBio has exited stealth with $85 million to discover and develop cell therapies. The biotech aims to differentiate itself from...

IPSEN BAGS BLUEPRINT DRUG TO MOVE DEEPER INTO ULTRA-RARE DISEASE

Ipsen has struck a deal with Blueprint Medicines to add another treatment for fibrodysplasia ossificans progressiva to its rare disease...

 
 
 

ALEXION INKS DEAL TO ACQUIRE ACHILLION FOR $930M UPFRONT

Alexion has struck a deal to buy Achillion for $930 million upfront. The takeover will give Alexion two clinical-phase medicines in...

MEDIMMUNE'S TOP CANCER RESEARCHER JUMPS SHIP TO SMALL BIOTECH

MedImmune's vice president of research and head of oncology R&D Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and...

 
 
 

ROCHE DUMPS EARLY PIPELINE EFFORTS AS SALES JUMP

Big Pharma giant Roche has quietly cut a series of early- to midstage experimental drugs as it continues the traditional quarterly...

LILLY'S ARMO BUYOUT DRUG A BUST IN PANCREATIC CANCER

Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.

 
 
 

HEALX RAISES $56M TO LAUNCH 40 RARE DISEASE R&D PROGRAMS

Healx has raised $56 million to launch 40 rare disease programs while taking some of its existing assets into the clinic. The ambitious...

BOEHRINGER'S VC WING BACKS ANTI-CANCER VIRUS STARTUP

Abalos Therapeutics has raised €12 million to discover and develop cancer drugs based on an arenavirus strain. The series A round sets...

 
 
 

WOODFORD CUT DOWN AS FUND CHOPPED AND BURNED

After being hailed as a near mystic when it came to stock picks, Britain's once great oak has been cut down to a sapling as Neil Woodford...

ELI LILLY TO SHUTTER NEUROSCIENCE R&D CENTER NEXT YEAR

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

 
 
 



World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study

SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study

An experimental breast cancer drug from Seattle Genetics is headed for FDA review after the company reported a pivotal clinical trial met its main goals. The company has been... Read more ...

Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer

Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer

Cancer therapies that harness the immune system don't work for all patients. Verseau Therapeutics aims to bring cancer immunotherapy to more people by targeting a type of... Read more ...

The secret of classic Belgian beers? Medieval super-yeasts

An international team of scientists led by Prof. Kevin Verstrepen and Prof. Steven Maere has discovered that some of the most renowned classic Belgian beers, including Gueuze... Read more ...

Edible grasshoppers can be modified for better fatty acid composition

It is possible to modify the fatty acid composition of edible grasshoppers by adding essential fatty acids in their feed, new research from the University of Eastern Finland... Read more ...

Manager, Engineering - Bachem - Vista, CA

The company provides a full range of services to the pharma and biotech industries. Handle complete project life cycle from design, planning and implementation...From Bachem... Read more ...

Bayer backs off running Casebia JV, as CRISPR Tx takes over management

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics, the German Pharma is now handing over the full reins... Read more ...

Uncovering the principles behind RNA folding

Using high-throughput next-generation sequencing technology, a researcher found similarities in the folding tendencies among a family of RNA molecules called riboswitches... Read more ...

Listening in to how proteins talk and learning their language

A research team has created a third approach to engineering proteins that uses deep learning to distill the fundamental features of proteins directly from their amino acid... Read more ...

Pinpointing biomolecules with nanometer accuracy

Scientists demonstrate a new approach in fluorescence microscopy that can be used to locate individual biomolecules in 3D space with nanometer-scale precision. Read more ...

How the mouse X and Y chromosomes compete with each other to control offspring

New research presents the first demonstration of a specific difference in sperm function associated with sex ratio skewing. Read more ...